Transcript Phase I

 Started:
- with $200,000 and 3 scientists
- in a small laboratory
at Seoul National University
- in November, 1996.
 First university-based
venture company in Korea
First gene medicine company in Korea
Seoul
National
University
High quality
Graduate Manpower
Students
Government
Intellectual Property
- Patents
Technology
- Scientific papers
Capital MOST
MOCIE
 Governmental support was instrumental at the commencement stage.
 However, the company needed a critical amount of money for growth.
 Domestic company was too conservative to invest in long-term, high
risk projects.
CEO: Sunyoung Kim, D. Phil.
Established: Nov. 21, 1996
Listed on Korean KOSDAQ market (December, 2005)
Total Personnel: 66
Market Cap: US $ 50 - 200 million
Most Active Biotech Company in Korea
- Phase II for 1 product (China)
- Phase I for 1 product (US, Korea and China)
- Phase I/II for 1 product (Korea)
- Phase I planned for 1 anti-cancer product in 2009 (Korea)
- Active R & D in progress for cancer and autoimmune diseases
Target Markets
US, Japan, EU, China, Korea, etc.
Global Competitiveness
- Out-licensing Records (UK, Japanese, and Chinese Companies)
- Global Capital Placement
- Patents Issued in Major Countries Including the US, Japan, EU, etc.
- Scientific Papers Published in Renowned International Scientific Journals
DNA-Based
Virus-Based
Recombinant
Protein
Retrovirus
Naked DNA
Phase II
Phase I/II
Phase I
Phase I
1
1
3
2
(Planned in 2009)
Adenovirus
VM202 (phase I)
Clinical
Trial
Critical Limb Ischemia
Coronary Artery Disease
VM206 (pre-clinical)
VM106 (phase I/II)
Chronic Granulomatous
Disease
VM501 (phase II)
Thrombocytopenia
Cancer (1)
Anti-Cancer Genetic Vaccine
R&D
Rheumatoid Arthritis
Autoimmune diseases(1)
Genetic Diseases
Cancer
Cancer
Psoriasis
Multiple Sclerosis
VM202
Angiogenic medicine for ischemic cardiovascular diseases
• Company’s proprietary expression system pCK
ColE1
p(HCMV)
• Designed to produce the two isoforms of human HGF
(723 and 728 amino acids)
e1
• Effects: Formation of new blood vessels
VM202
(Kanr )
(Backbone: pCK)
pA(BGH)
e2
• Patents: Issued in Japan, Europe, Korea, Singapore,
China and Hong Kong
and filed in the US and Brazil
Target: Coronary Artery Disease
No. 1 or 2 cause of death in all major countries
Direct Injection
Catheter
Drug-Eluting Stent
World market size of gene medicine for cardiovascular diseases:
> $3.3 B by year 2015 (Jain Pharmabiotech, 2006)
Day 1 (Pre-dose)
Target : Peripheral Artery Disease
Day 59
(Ischemic Limb Disease)
Day 1 (Pre-dose)
Day 15
Day 1 (Pre-dose)
- Hospitalization of about 250,000 patients annually in the US
- World market size in peripheral artery disease: $1.5B (DataMonitor, 2004)
Day 90
VM202
Coronary Artery Disease
(Myocardial Infarction, Angina Pectoris)
A leading cause of death in developed countries
911,000 deaths annually in the US
Approximately 16 million patients in the US experience CAD
Peripheral Artery Disease
Diabetic Neuropathy
Estimated 8 million Americans (symptoms of PAD)
About 250,000 patients hospitalized annually in the US
Direct
Muscle Injection
Direct injection
on Heart muscle
Phase I
(Korea)
Ongoing
(6/9)
By Catheter
Drug-Eluting Stent
Phase I
(US)
2009
Pre-clinical
Phase I
(US)
Enrollment
completed
(12/12)
Phase I
(China)
Enrollment
started
(0/21)
Phase I/II
(US)
Planned for DN
Cancer
patient
VM501
Original wild type IL-11
→ Highly toxic
Genetically
Modified IL-11
Antibody
Her2
Her2 expressing
cancer cells
CTL
IND Submission in 1Q, 2009. Phase I trial planned in 3Q, 2009.
Pre-clinical experiments have been completed in murine, canine, and primate models.
DNA-Based
Virus-Based
Recombinant
Protein
Retrovirus
Naked DNA
Phase II
Phase I/II
Phase I
Phase I
1
1
3
2
(Planned in 2009)
Adenovirus
VM202 (phase I)
Clinical
Trial
Critical Limb Ischemia
Coronary Artery Disease
VM206 (pre-clinical)
VM106 (phase I/II)
Chronic Granulomatous
Disease
VM501 (phase II)
Thrombocytopenia
Cancer (1)
Anti-Cancer Genetic Vaccine
R&D
Rheumatoid Arthritis
Autoimmune diseases(1)
Genetic Diseases
Cancer
Cancer
Psoriasis
Multiple Sclerosis
ViroMed has grown from a small university-born company
to one of the most active biopharmaceutical companies in Asia.
ViroMed has developed 4 products, that are under
phase I or phase II human trials in the US, China, and Korea.
In addition, 2 products are being actively developed
for cancer and autoimmune diseases.
ViroMed is a multi-portfolio biopharmaceutical company
with solid multiple technology platforms.
ViroMed is a unique and sophisticated biotech company,
poised to become a significant global player in the field.